VALENCIA, Calif.--(BUSINESS WIRE)--Nov 18, 2024-- SetPoint Medical , a clinical-stage healthcare company dedicated to people living with chronic autoimmune diseases, today announced late-breaking data from the RESET-RA study presented at the American College of Rheumatology (ACR) Convergence 2024, the largest global gathering of rheumatologists. New clinical trial results support the SetPoint System's potential as a first-of-its-kind neuroimmune modulation treatment for adults living with moderate-to-severe rheumatoid arthritis (RA) who are incomplete responders or intolerant to at least one biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs).
This press release features multimedia. View the full release here: https://www.businesswire.
com/news/home/20241118507235/en/ (Photo: SetPoint Medical) SetPoint Medical previously announced the primary efficacy endpoint of ACR20 response was met in the RESET-RA study, which enrolled 242 participants. An ACR20 response is a composite measure of the effectiveness of RA treatments set forth by the American College of Rheumatology. “Despite treatment advancements, several challenges and unmet medical needs remain for more than 1.
5 million adults in the United States who are living with rheumatoid arthritis and its disabling impact,” said John Tesser, MD, FACP, FACR, MACR of Arizona Arthritis & Rheumatology Associates in Phoenix, AZ, and national rheumatologist principal investigator of the study. “The re.
